Cirrhosis is diagnosed through a combination of blood tests, imaging, and sometimes a physical exam, with liver biopsy reserved for cases where non-invasive methods can’t provide a clear answer. In many cases, doctors can confirm cirrhosis without a biopsy at all, using newer tools like elastography (a specialized ultrasound that measures liver stiffness) alongside standard lab work and imaging.
What Doctors Look for on Physical Exam
A physical exam alone can’t confirm cirrhosis, but it can raise strong suspicion. Several visible signs point toward chronic liver damage. Spider nevi, tiny red spots with small blood vessels radiating outward like spider legs, appear on the skin because the damaged liver can’t properly regulate estrogen levels. The same hormone imbalance causes palmar erythema, a reddish discoloration of the palms. In men, it can also lead to breast tissue enlargement and testicular shrinkage.
More advanced cirrhosis produces signs related to increased pressure in the portal vein, the major blood vessel feeding the liver. Fluid can accumulate in the abdomen (ascites), the spleen may enlarge, and visible veins can fan out from the belly button across the abdomen, a pattern called caput medusae. Yellowing of the skin and eyes (jaundice) signals that bilirubin, a waste product the liver normally clears, is building up in the blood.
Blood Tests That Flag Liver Damage
A standard liver panel measures several markers that together paint a picture of how well the liver is functioning. Two liver enzymes, ALT and AST, indicate ongoing damage to liver cells. Normal ALT runs 7 to 55 units per liter, and normal AST runs 8 to 48. In cirrhosis, these can be elevated, though they sometimes drop back to normal in very advanced disease when there’s little functioning liver tissue left to release them.
Other markers reveal how well the liver is doing its job. Albumin, a protein the liver produces, normally sits between 3.5 and 5.0 grams per deciliter. Low albumin suggests the liver is struggling to keep up with production. Bilirubin, normally 0.1 to 1.2 milligrams per deciliter, rises when the liver can’t process waste efficiently. Prothrombin time, which measures how quickly your blood clots, normally falls between 9.4 and 12.5 seconds. A longer clotting time means the liver isn’t making enough clotting factors.
Platelet count is another important clue. Up to 76% of people with chronic liver disease have low platelet counts (below 150,000 per microliter), and the rate is even higher among those with cirrhosis. While there’s no single platelet number that confirms the diagnosis, a progressive decline in platelets alongside other abnormal liver markers strengthens the case considerably.
Non-Invasive Fibrosis Scoring
Before ordering imaging or a biopsy, many doctors use simple scoring formulas that combine routine blood test results to estimate fibrosis severity. The FIB-4 index is one of the most widely used. It calculates a score from just four inputs: your age, AST level, ALT level, and platelet count. A high FIB-4 score suggests significant scarring and prompts further investigation, while a low score can help rule out advanced fibrosis without additional testing.
Imaging: Ultrasound, CT, and MRI
Abdominal imaging gives doctors a direct look at the liver’s size, shape, and surrounding structures. On ultrasound, CT, or MRI, several features suggest cirrhosis: a nodular, bumpy liver surface instead of a smooth one, a shrunken right lobe with an enlarged left lobe or caudate lobe, an enlarged spleen, visible collateral blood vessels or varices (dilated veins that form when blood reroutes around the scarred liver), and free fluid in the abdomen.
Ultrasound is typically the first imaging test ordered because it’s inexpensive, widely available, and involves no radiation. CT and MRI provide more detail when the ultrasound findings are unclear or when doctors need to check for complications like liver cancer.
Elastography: Measuring Liver Stiffness
Transient elastography, commonly known by the brand name FibroScan, has become one of the most important non-invasive diagnostic tools. It works by sending a painless vibration pulse through the liver and measuring how quickly the wave travels. Stiffer tissue (more scarring) transmits the wave faster, producing a higher reading in kilopascals (kPa).
The results map to fibrosis stages on the METAVIR scale, which runs from F0 (no fibrosis) to F4 (cirrhosis). A reading of 7.2 kPa or above suggests at least moderate fibrosis. At 12.5 kPa and above, severe fibrosis is likely. A reading of 17.6 kPa or higher carries a positive predictive value of at least 90% for cirrhosis. Published studies place the cirrhosis cutoff somewhere between 12.5 and 17.6 kPa depending on the underlying cause of liver disease, so your doctor interprets the number in context rather than relying on a single threshold.
When a Liver Biopsy Is Still Needed
Liver biopsy was once considered the gold standard for diagnosing cirrhosis, but its role has narrowed significantly. Current guidelines from the British Society of Gastroenterology state that biopsy is warranted only when clinically important information about diagnosis, prognosis, or treatment can’t be obtained through safer methods. With improvements in blood-based scoring, elastography, and imaging, many diagnoses no longer depend on biopsy at all, and patients overwhelmingly prefer non-invasive alternatives.
Biopsy still plays a role when the cause of liver disease is uncertain, when multiple liver conditions may be present at the same time, or when the non-invasive results conflict with each other. During the procedure, a thin needle extracts a small core of liver tissue for examination under a microscope, where a pathologist can directly see the pattern and extent of scarring.
Staging Severity After Diagnosis
Once cirrhosis is confirmed, the next step is determining how much liver function remains. Two scoring systems are used for this, and they serve different purposes.
The Child-Pugh score adds up points based on five factors: bilirubin level, albumin level, clotting time (INR), the presence and severity of ascites, and the presence and severity of hepatic encephalopathy (confusion and cognitive changes caused by toxin buildup). Each factor scores 1 to 3 points. A total of 5 to 6 points is Class A, meaning the liver is still relatively well-compensated. Seven to 9 points is Class B, indicating significant impairment. Ten to 15 points is Class C, the most severe category.
The MELD score (Model for End-Stage Liver Disease) is used primarily to prioritize patients for liver transplantation. It’s calculated from lab values including creatinine (a kidney function marker), bilirubin, INR, sodium, and albumin, along with the patient’s age and sex. A higher MELD score indicates more urgent need for transplant.
Compensated vs. Decompensated Cirrhosis
Cirrhosis isn’t a single state. It progresses through stages that carry very different outlooks. In compensated cirrhosis, the liver is scarred but still handling most of its workload. You may have no symptoms at all, or only mild ones. The one-year mortality rate at this stage is low, between 1% and 3%, depending on whether enlarged veins (varices) have developed.
Decompensated cirrhosis means complications have appeared: fluid buildup in the abdomen, confusion from hepatic encephalopathy, or bleeding from varices. The shift from compensated to decompensated happens at a rate of about 5% to 7% per year. Once it occurs, the prognosis changes dramatically. Patients with ascites face a one-year mortality rate of roughly 20%, and those who’ve experienced variceal bleeding face a rate of about 57%. This is why early detection matters so much. Identifying cirrhosis while it’s still compensated opens a wider window for treatment and monitoring that can delay or prevent decompensation.